Press Releases Press Releases Year None20202019201820172016201520142013201120102009200820072005 August 4, 2020 Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast PDF Version June 29, 2020 Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure PDF Version May 14, 2020 Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference PDF Version May 13, 2020 Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders PDF Version May 7, 2020 Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update PDF Version April 29, 2020 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast PDF Version April 16, 2020 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version April 2, 2020 Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults PDF Version March 23, 2020 Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia PDF Version March 2, 2020 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update PDF Version Pagination Current page 1 Page 2 Next page next › Last page last »
August 4, 2020 Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast PDF Version
June 29, 2020 Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure PDF Version
May 14, 2020 Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference PDF Version
May 7, 2020 Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update PDF Version
April 29, 2020 Intra-Cellular Therapies to Host First Quarter 2020 Financial Results Conference Call and Webcast PDF Version
April 16, 2020 Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version
April 2, 2020 Intra-Cellular Therapies Initiates Promotional Activities for CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults PDF Version
March 23, 2020 Intra-Cellular Therapies Announces Availability of CAPLYTA™ (lumateperone) for Adult Patients with Schizophrenia PDF Version
March 2, 2020 Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update PDF Version
